185 related articles for article (PubMed ID: 21763262)
1. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.
Swarts DR; Claessen SM; Jonkers YM; van Suylen RJ; Dingemans AM; de Herder WW; de Krijger RR; Smit EF; Thunnissen FB; Seldenrijk CA; Vink A; Perren A; Ramaekers FC; Speel EJ
Am J Pathol; 2011 Sep; 179(3):1129-37. PubMed ID: 21763262
[TBL] [Abstract][Full Text] [Related]
2. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
3. Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study.
Petzmann S; Ullmann R; Halbwedl I; Popper HH
Virchows Arch; 2004 Aug; 445(2):151-9. PubMed ID: 15235910
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity on chromosome arm 11q in lung carcinoids.
Petzmann S; Ullmann R; Klemen H; Renner H; Popper HH
Hum Pathol; 2001 Mar; 32(3):333-8. PubMed ID: 11274644
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids.
Kytölä S; Höög A; Nord B; Cedermark B; Frisk T; Larsson C; Kjellman M
Am J Pathol; 2001 May; 158(5):1803-8. PubMed ID: 11337378
[TBL] [Abstract][Full Text] [Related]
6. High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids.
Andersson E; Swärd C; Stenman G; Ahlman H; Nilsson O
Endocr Relat Cancer; 2009 Sep; 16(3):953-66. PubMed ID: 19458023
[TBL] [Abstract][Full Text] [Related]
7. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
9. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization.
Ullmann R; Schwendel A; Klemen H; Wolf G; Petersen I; Popper HH
Hum Pathol; 1998 Oct; 29(10):1145-9. PubMed ID: 9781656
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome.
D'Adda T; Keller G; Bordi C; Höfler H
Lab Invest; 1999 Jun; 79(6):671-7. PubMed ID: 10378509
[TBL] [Abstract][Full Text] [Related]
11. Genetic changes in the spectrum of neuroendocrine lung tumors.
Onuki N; Wistuba II; Travis WD; Virmani AK; Yashima K; Brambilla E; Hasleton P; Gazdar AF
Cancer; 1999 Feb; 85(3):600-7. PubMed ID: 10091733
[TBL] [Abstract][Full Text] [Related]
12. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.
Swarts DR; Scarpa A; Corbo V; Van Criekinge W; van Engeland M; Gatti G; Henfling ME; Papotti M; Perren A; Ramaekers FC; Speel EJ; Volante M
J Clin Endocrinol Metab; 2014 Feb; 99(2):E374-8. PubMed ID: 24276465
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome.
Ambatipudi S; Gerstung M; Gowda R; Pai P; Borges AM; Schäffer AA; Beerenwinkel N; Mahimkar MB
PLoS One; 2011 Feb; 6(2):e17250. PubMed ID: 21386901
[TBL] [Abstract][Full Text] [Related]
14. An exploration of pathways involved in lung carcinoid progression using gene expression profiling.
Swarts DR; Van Neste L; Henfling ME; Eijkenboom I; Eijk PP; van Velthuysen ML; Vink A; Volante M; Ylstra B; Van Criekinge W; van Engeland M; Ramaekers FC; Speel EJ
Carcinogenesis; 2013 Dec; 34(12):2726-37. PubMed ID: 23929435
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
16. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
D'Adda T; Bottarelli L; Azzoni C; Pizzi S; Bongiovanni M; Papotti M; Pelosi G; Maisonneuve P; Antonetti T; Rindi G; Bordi C
Mod Pathol; 2005 Jun; 18(6):795-805. PubMed ID: 15578070
[TBL] [Abstract][Full Text] [Related]
17. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.
Debelenko LV; Brambilla E; Agarwal SK; Swalwell JI; Kester MB; Lubensky IA; Zhuang Z; Guru SC; Manickam P; Olufemi SE; Chandrasekharappa SC; Crabtree JS; Kim YS; Heppner C; Burns AL; Spiegel AM; Marx SJ; Liotta LA; Collins FS; Travis WD; Emmert-Buck MR
Hum Mol Genet; 1997 Dec; 6(13):2285-90. PubMed ID: 9361035
[TBL] [Abstract][Full Text] [Related]
18. The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues.
Ullmann R; Petzmann S; Klemen H; Fraire AE; Hasleton P; Popper HH
Genes Chromosomes Cancer; 2002 May; 34(1):78-85. PubMed ID: 11921285
[TBL] [Abstract][Full Text] [Related]
19. Interobserver variability for the WHO classification of pulmonary carcinoids.
Swarts DR; van Suylen RJ; den Bakker MA; van Oosterhout MF; Thunnissen FB; Volante M; Dingemans AM; Scheltinga MR; Bootsma GP; Pouwels HM; van den Borne BE; Ramaekers FC; Speel EJ
Am J Surg Pathol; 2014 Oct; 38(10):1429-36. PubMed ID: 25046341
[TBL] [Abstract][Full Text] [Related]
20. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
